Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
Active, not recruiting · NCT02345265 · Registry updated 2026-09-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube carcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, primary peritoneal carcinoma, primary peritoneal serous adenocarcinoma | Active, not recruiting | Phase 2 | 2026-09-29 | NCT02345265 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
20 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.